OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Hamid on the Potential for Cancer Vaccines in Melanoma

February 12th 2025

Omid Hamid, MD, provides insight on the potential role of cancer vaccines in melanoma.

Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma

February 11th 2025

Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.

Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma

February 11th 2025

Mark Faries, MD, discusses how CAR T-cell and TCR cell therapies compare with TIL approaches in melanoma.

Dr Moertel on the FDA Approval of Mirdametinib for NF1-Associated Plexiform Neurofibromas

February 11th 2025

Christopher L. Moertel, MD, discusses the FDA approval of mirdametinib for patients with neurofibromatosis type 1–associated plexiform neurofibromas.

Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia

February 11th 2025

Elias Jabbour, MD, discusses data for bleximenib in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements or NPM1 mutations.

Dr Lang on Real-World Outcomes With the KEYNOTE-522 Regimen in Early-Stage TNBC

February 11th 2025

Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.

Dr McNall-Knapp on HRQOL Outcomes With Mirdametinib in NF1-PN

February 10th 2025

Rene Y. McNall-Knapp, MD, discusses HRQOL outcomes from the ReNeu trial investigating mirdametinib in patients with NF1-PN.

Dr Livingston on the Addition of Hydroxychloroquine to Gemcitabine/Docetaxel in Osteosarcoma

February 10th 2025

John Andrew Livingston, MD, MS, discusses responses with gemcitabine, docetaxel, and hydroxychloroquine in advanced, metastatic osteosarcoma.

Dr Colman on Outcomes With Eflornithine in Grade 3 Anaplastic Astrocytoma

February 10th 2025

Howard Colman, MD, PhD, discusses the STELLAR trial of eflornithine plus lomustine vs lomustine alone in recurrent, IDH-mutant, anaplastic astrocytoma.

Dr Moore on the 2024 FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer

February 10th 2025

Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.

Dr Yaeger on the Efficacy of Adagrasib/Cetuximab in KRAS G12C+ mCRC

February 10th 2025

Rona Yaeger, MD, details the efficacy of adagrasib/cetuximab in heavily pretreated patients with KRAS G12C–mutant mCRC.

Dr Ascierto on First-Line Treatment Selection in Advanced BRAF+ Melanoma

February 8th 2025

Paolo A. Ascierto, MD, discusses findings from the SECOMBIT and DREAMseq trials and their implications for first-line treatment selection for patients with BRAF-mutant melanoma.

Dr Robert on the Role of Adjuvant Anti–PD-1 Therapy in Resected Stage IIB/C Melanoma

February 8th 2025

Caroline Robert, MD, PhD, discusses the role of adjuvant anti–PD-1 therapy in resected stage IIB/IIC melanoma based on findings from the KEYNOTE-716 and CheckMate 76K trials.

Dr Nguyen on Updated NCCN Guidelines for Non–Clear Cell RCC

February 7th 2025

Charles B. Nguyen, MD, discusses the updated 2024 NCCN Guidelines and their effect on treatment decisions for non–clear cell RCC.

Dr Lin on Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

February 7th 2025

Yi Lin, MD, PhD, discuses cilta-cel vs standard of care in patients with lenalidomide-refractory multiple myeloma.

Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC

February 7th 2025

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab for adult patients with KRAS G12C–mutated metastatic colorectal cancer.

Dr Al Malki on Reducing Relapse Risk in Patients with MDS Undergoing Haplo-HSCT

February 7th 2025

Monzr M. Al Malki, MD, discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation.

Dr Krop on Zanidatamab Plus Evorpacept in HER2+ Metastatic Breast Cancer

February 7th 2025

Ian Krop, MD, PhD, discusses zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Dr Fenske on the Rationale of Assessing Rituximab With or Without ASCT in MRD-Negative MCL

February 6th 2025

Timothy S. Fenske, MD, MS, details the rationale of a phase 3 trial assessing rituximab with or without ASCT in mantle cell lymphoma.

Dr Garrido-Laguna on the Safety and Efficacy of Daraxonrasib in KRAS-Mutated PDAC

February 6th 2025

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses updated safety and efficacy data with daraxonrasib in KRAS-mutated pancreatic ductal adenocarcinoma.